{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:01:30Z","timestamp":1783468890321,"version":"3.55.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Radiotherapy is a definitive treatment for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome with solitary plasmacytoma. However, data on its efficacy and the role of immunochemotherapy are limited. This study evaluated the treatment outcomes of patients with POEMS syndrome receiving radiotherapy as their primary therapy and compared the results of those treated with adjunctive immunochemotherapy with those without. A retrospective analysis of patients with POEMS syndrome referred to the University College London Hospital from 1998 to 2023 was conducted. Among 150 patients with POEMS syndrome, 30 (20%) presented with solitary plasmacytoma. Sixteen patients (53%) received radiotherapy alone, whereas 14 (47%) had combined treatment with radiotherapy and immunochemotherapy, predominantly lenalidomide, and dexamethasone. Treatment responses were greater in the combined treatment group, with clinical, vascular endothelial growth factor, hematological, and radiological responses of 100%, 92%, 100%, and 100%, respectively, compared with 87%, 92%, 85%, and 79% in patients receiving radiotherapy only. The median follow-up for the entire cohort was 124 months, with a 5-year overall survival rate of 100% and a progression-free survival (PFS) rate of 82%. For those receiving radiotherapy alone, the median follow-up was 124 months, with a 3-year PFS rate of 69%. In contrast, no progression was observed among patients treated with combined therapy during the follow-up period (range, 7-54 months). Six patients experienced disease progression, with all having received radiotherapy alone as their first-line treatment. This study demonstrated the high efficacy of radiotherapy in patients with POEMS syndrome and solitary plasmacytoma and highlighted the potential benefits of combining radiotherapy with immunochemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018944","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:21:05Z","timestamp":1769102465000},"page":"2074-2081","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-0639","authenticated-orcid":false,"given":"Grace","family":"Lau","sequence":"first","affiliation":[{"name":"1Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavitha","family":"Vivekananthan","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-2906","authenticated-orcid":false,"given":"Oliver","family":"Tomkins","sequence":"additional","affiliation":[{"name":"1Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karimali","family":"Keshwani","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6914-4179","authenticated-orcid":false,"given":"Suganya","family":"Sivabalasingham","sequence":"additional","affiliation":[{"name":"2Department of Oncology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[{"name":"3Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P.","family":"Lunn","sequence":"additional","affiliation":[{"name":"4Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"1Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-2793","authenticated-orcid":false,"given":"Jonathan","family":"Sive","sequence":"additional","affiliation":[{"name":"1Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"11","key":"2026032014072243700_bib1","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1097\/HS9.0000000000000796","article-title":"Comprehensive diagnosis and management of POEMS syndrome","volume":"6","author":"D\u2019Sa","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2026032014072243700_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","article-title":"Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience","volume":"120","author":"D\u2019Souza","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2026032014072243700_bib3","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2026032014072243700_bib4","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1212\/WNL.0000000000009940","article-title":"Clinical characteristics, risk factors, and outcomes of POEMS syndrome: a longitudinal cohort study","volume":"95","author":"Keddie","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"2026032014072243700_bib5","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/bloodadvances.2020001492","article-title":"High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS registry","volume":"4","author":"Sayar","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026032014072243700_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","article-title":"Outcomes of patients with POEMS syndrome treated initially with radiation","volume":"122","author":"Humeniuk","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2026032014072243700_bib7","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026032014072243700_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23201","article-title":"Trends and outcomes of modern staging of solitary plasmacytoma of bone","volume":"87","author":"Warsame","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"2026032014072243700_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijrobp.2008.08.037","article-title":"Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma","volume":"74","author":"Kim","year":"2009","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"2026032014072243700_bib10","first-page":"841","article-title":"Positron emission tomography (PET) for staging of solitary plasmacytoma","volume":"18","author":"Schirrmeister","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2026032014072243700_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European expert panel","volume":"11","author":"Caers","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2026032014072243700_bib12","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026032014072243700_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol"},{"issue":"1","key":"2026032014072243700_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"2026032014072243700_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00259-017-3810-5","article-title":"18F\u2013FDG PET\/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma","volume":"45","author":"Albano","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2026032014072243700_bib16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/blood-2014-04-566521","article-title":"Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis","volume":"124","author":"Hill","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026032014072243700_bib17","doi-asserted-by":"crossref","first-page":"1300.EP","DOI":"10.1182\/blood-2014-04-567909","article-title":"Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026032014072243700_bib18","doi-asserted-by":"crossref","first-page":"111.EP","DOI":"10.1002\/(SICI)1099-1069(199609)14:3<111::AID-HON575>3.0.CO;2-G","article-title":"Improved outcome in solitary bone plasmacytomata with combined therapy","volume":"14","author":"Aviles","year":"1996","journal-title":"Hematol Oncol"},{"issue":"1","key":"2026032014072243700_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol"},{"issue":"8","key":"2026032014072243700_bib20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23745","article-title":"Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek Myeloma Study Group in 97 patients","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"2026032014072243700_bib21","doi-asserted-by":"crossref","first-page":"2810.EP","DOI":"10.1080\/10428194.2019.1605067","article-title":"New insights in the treatment of patients with solitary bone plasmacytoma","volume":"60","author":"Mheidly","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2026032014072243700_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ijrobp.2019.10.043","article-title":"Solitary plasmacytoma treated by lenalidomide-dexamethasone in combination with radiation therapy: clinical outcomes","volume":"106","author":"Mignot","year":"2020","journal-title":"Int J Radiat Oncol"},{"issue":"11","key":"2026032014072243700_bib23","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3324\/haematol.2022.282214","article-title":"Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma","volume":"108","author":"Ascione","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026032014072243700_bib24","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1182\/blood-2022-158528","article-title":"Adjuvant systemic therapy in high risk solitary bone plasmacytoma: results of the UK randomised phase III IDRIS study (CR UK\/14\/032)","volume":"140","author":"Ediriwickrema","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026032014072243700_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bjh.18400","article-title":"Evidence-based medical treatment of POEMS syndrome","volume":"200","author":"Khwaja","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2026032014072243700_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13014-014-0265-8","article-title":"The role of radiotherapy in the management of POEMS syndrome","volume":"9","author":"Suh","year":"2014","journal-title":"Radiat Oncol"},{"issue":"13","key":"2026032014072243700_bib27","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2074\/2509466\/blooda_adv-2025-018944-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2074\/2509466\/blooda_adv-2025-018944-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:07:32Z","timestamp":1774030052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/2074\/566206\/Efficacy-of-radiotherapy-and-role-of-adjunctive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018944","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,16]]}}}